Trials / Conditions / HER2-Negative Breast Carcinoma

HER2-Negative Breast Carcinoma

25 registered clinical trials studyying HER2-Negative Breast Carcinoma — 18 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy Wi NCT07391774	National Cancer Institute (NCI)	Phase 3
Suspended	Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer NCT07136493	City of Hope Medical Center	N/A
Recruiting	A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer NCT07483307	Memorial Sloan Kettering Cancer Center	Phase 2
Not Yet Recruiting	Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Tri NCT07276880	UNC Lineberger Comprehensive Cancer Center	Phase 2
Recruiting	Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer NCT07085767	Olema Pharmaceuticals, Inc.	Phase 3
Recruiting	Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer NCT06774027	University of California, San Francisco	—
Suspended	Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial NCT06671912	Alliance for Clinical Trials in Oncology	Phase 3
Recruiting	Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women Wi NCT06534125	Emory University	N/A
Recruiting	A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer NCT06678269	Memorial Sloan Kettering Cancer Center	Phase 1
Recruiting	Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoin NCT06450873	Mayo Clinic	Phase 2
Recruiting	Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 NCT06042569	City of Hope Medical Center	Phase 2
Recruiting	Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Na NCT06026657	Margaret Gatti-Mays	Phase 1 / Phase 2
Recruiting	Mobile Health for Adherence in Breast Cancer Patients NCT06112613	ECOG-ACRIN Cancer Research Group	N/A
Recruiting	DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs NCT06176261	Sarah Sammons, MD	Phase 2
Recruiting	Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclopho NCT06058377	National Cancer Institute (NCI)	Phase 3
Recruiting	OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer NCT06016738	Olema Pharmaceuticals, Inc.	Phase 3
Suspended	Evaluation of a Once Per Day Regimen of Accelerated Partial Breast Irradiation for Improved Breast Appearance NCT06008158	City of Hope Medical Center	Phase 2
Terminated	A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer Patients to Improve Adhe NCT05488145	Emory University	N/A
Recruiting	Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cance NCT05677802	Ohio State University Comprehensive Cancer Center	N/A
Recruiting	Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negati NCT05464810	Emory University	EARLY_Phase 1
Recruiting	Neoadjuvant Breast Cancer Time Restricted Eating NCT05327608	Thomas Jefferson University	N/A
Active Not Recruiting	Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiv NCT04379570	Alliance for Clinical Trials in Oncology	Phase 3
Recruiting	SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells NCT04150042	General Oncology, Inc.	Phase 1
Active Not Recruiting	Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemo NCT04052555	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer NCT02157051	University of Washington	Phase 1